» Articles » PMID: 19399775

Quantification of Hepcidin Using Matrix-assisted Laser Desorption/ionization Time-of-flight Mass Spectrometry

Overview
Specialty Chemistry
Date 2009 Apr 29
PMID 19399775
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Hepcidin is known to be a key systemic iron-regulatory hormone which has been demonstrated to be associated with a number of iron disorders. Hepcidin concentrations are increased in inflammation and suppressed in hemochromatosis. In view of the role of hepcidin in disease, its potential as a diagnostic tool in a clinical setting is evident. This study describes the development of a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) assay for the quantitative determination of hepcidin concentrations in clinical samples. A stable isotope labeled hepcidin was prepared as an internal standard and a standard quantity was added to urine samples. Extraction was performed with weak cation-exchange magnetic nanoparticles. The basic peptides were eluted from the magnetic nanoparticles using a matrix solution directly onto a target plate and analyzed by MALDI-TOF MS to determine the concentration of hepcidin. The assay was validated in charcoal stripped urine, and good recovery (70-80%) was obtained, as were limit of quantitation data (5 nmol/L), accuracy (RE <10%), precision (CV <21%), within -day repeatability (CV <13%) and between-day repeatability (CV <21%). Urine hepcidin levels were 10 nmol/mmol creatinine in healthy controls, with reduced levels in hereditary hemochromatosis (P < 0.000005) and elevated levels in inflammation (P < 0.0007). In summary a validated method has been developed for the determination of hepcidin concentrations in clinical samples.

Citing Articles

Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.

Garbowski M, Bansal S, Porter J, Mori C, Burckhardt S, Hider R Haematologica. 2020; 106(11):2885-2896.

PMID: 33054113 PMC: 8561294. DOI: 10.3324/haematol.2020.250803.


Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.

Porter J, Cappellini M, Kattamis A, Viprakasit V, Musallam K, Zhu Z Br J Haematol. 2016; 176(2):288-299.

PMID: 27917462 PMC: 5248634. DOI: 10.1111/bjh.14373.


Copper(II) binding properties of hepcidin.

Kulprachakarn K, Chen Y, Kong X, Arno M, Hider R, Srichairatanakool S J Biol Inorg Chem. 2016; 21(3):329-38.

PMID: 26883683 PMC: 4850187. DOI: 10.1007/s00775-016-1342-2.


Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.

Porter J, Walter P, Neumayr L, Evans P, Bansal S, Garbowski M Br J Haematol. 2014; 167(5):692-6.

PMID: 25209728 PMC: 4577015. DOI: 10.1111/bjh.13081.


Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids.

Fan J, Niu S, Dong A, Shi J, Wu H, Fine D Nanomedicine. 2014; 10(5):879-88.

PMID: 24566273 PMC: 4077980. DOI: 10.1016/j.nano.2014.02.005.